U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07088926) titled 'A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization' on July 17.
Brief Summary: AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
Study Start Date: Nov. 12, 2025
Study Type: INTERVENTIONAL
Condition:
Bronchiectasis With Pseudomonas Aeruginosa Colonization
Intervention:
BIOLOGICAL: AZD0292
AZD0292 high-dose or low-dose administered starting on Day 1 via IV infusion, subsequent administrations per sched...